-
Puma licences breast cancer therapy to Pierre Fabre in Europe
pharmaceutical-technology
April 23, 2019
Puma licences breast cancer therapy to Pierre Fabre in Europe.
-
Puma Biotechnology and Pierre Fabre enter into an exclusive license agreement for the development and marketing of NERLYNX? (neratinib)
pharmafocusasia
April 03, 2019
Puma Biotechnology, Inc and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and market NERLYNX? (neratinib) in Europe and in some regions of Africa. In September 2018...
-
Pierre Fabre to launch blockchain patient engagement pilot
pharmaphorum
December 18, 2018
Pierre Fabre Pharmaceuticals has joined a blockchain consortium that allows patients to share real-time digital health data to inform late-stage clinical research.
-
Steriline Technologies and Innovative Solutions for a longstanding relationship with pharma customers
cphi-online
November 15, 2018
An unequalled expertise in the aseptic processing and a well-known ability to answer customers’ needs made Steriline the perfect ally for pharmaceutical companies: Pierre Fabre case history
-
Pierre Fabre secures Italian distribution rights for Noventure's Aprotecol
pharmafile
July 18, 2017
Noventure has allied with Pierre Fabre Pharma Italy in a partnership which will see the latter distribute the Spanish start-up’s paediatric intestinal treatment Aprotecol in Italy.
-
Pierre Fabre Buys Igenica Immuno-oncology Assets
contractpharma
May 26, 2017
Deal reinforces Pierre Fabre’s pipeline in oncology, its primary R&D focus area
-
Pierre Fabre and H-Immune Announce Strategic Research Partnership to Develop Potentially Ground-Brea
americanpharmaceuticalreview
March 23, 2017
Pierre Fabre have entered into a strategic research partnership which will utilize H-Immune’s unique technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutic
-
Pierre Fabre and H-Immune Announce Strategic Research Partnership to Develop Potentially Ground-Brea
firstwordpharma
March 22, 2017
Pierre Fabre, the second largest privately held pharmaceutical company in France, and H-Immune SAS, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, today announced that they have ent
-
Pierre Fabre and Hill Dermaceuticals Announce Strategic Commercial Partnership for TOLAK? Cream 4%
americanpharmaceuticalreview
March 07, 2017
Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/
-
PIQUR and PIERRE FABRE Announce Partnership in Dermato-Oncology
americanpharmaceuticalreview
January 13, 2017
PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, and Pierre Fabre, the second largest private French pharmaceutical group have signed a collaboration agreement for the development of PIQUR's lead compound PQR309 in dermato-oncology.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
